KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Shares Issued (2016 - 2025)

Pacira BioSciences (PCRX) has 15 years of Shares Issued data on record, last reported at $490000.0 in Q4 2025.

  • For Q4 2025, Shares Issued changed N/A year-over-year to $490000.0; the TTM value through Dec 2025 reached $490000.0, changed N/A, while the annual FY2025 figure was $502000.0, N/A changed from the prior year.
  • Shares Issued reached $490000.0 in Q4 2025 per PCRX's latest filing, up from $26000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $11.0 million in Q1 2022 and bottomed at $26000.0 in Q3 2023.
  • Average Shares Issued over 4 years is $4.2 million, with a median of $2.3 million recorded in 2021.
  • Peak YoY movement for Shares Issued: skyrocketed 198.84% in 2021, then tumbled 98.38% in 2023.
  • A 4-year view of Shares Issued shows it stood at $4.8 million in 2021, then tumbled by 81.13% to $905000.0 in 2022, then tumbled by 97.13% to $26000.0 in 2023, then surged by 1784.62% to $490000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $490000.0 in Q4 2025, $26000.0 in Q3 2023, and $1.6 million in Q2 2023.